The maker of infant formula has operated the Georgia site since 2010 but told VTDigger last year that the current situation there was “not cost-effective.” ...

Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded ...

PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant ...

Q1 2026 earnings call recap: guidance reaffirmed, store-brand OTC share gains, margins/costs, divestiture and risks—read key takeaways.

Patrick Lockwood-Taylor, President, CEO & Director, began by emphasizing Perrigo's "meaningful progress" in 2025, stating, "We are winning with consumers and customers, and that momentum is reflected ...

Perrigo's strategic focus on consumer self-care products and divestment of non-core assets positions it for strong growth and higher margins. The company's extensive product range and regulatory ...

Organic net sales CAGR of 2.5% – 4.5% Adjusted EPS CAGR of high-single to low-double-digit % Adjusted operating margin expansion of +150 to +250 basis points by 2027 Apart from this, the company ...

Credit: Perrigo. Opill will be available for purchase at a price of $19.99 for a 1-month pack, $49.99 for a 3-month supply and $89.99 for a 6-month supply. Opill ®, a progestin-only daily oral ...

GRAND RAPIDS, Mich. (WOOD) — The first over-the-counter birth control pill is expected to hit stores soon. As first reported by News 8 partner Crain’s Grand Rapids Business, Perrigo will be launching ...

Perrigo’s performance has been mixed, with management changes, integration issues, the return of branded competitors to store shelves, and competitive pressure in the prescription topicals business.